TipRanks (Thu, 15-Oct 12:30 PM ET)
Adlai Nortye Strikes Global Clinical Collaboration with Lilly and Merck for AN4035 Combination Trial
TipRanks (Thu, 15-Oct 7:31 AM ET)
Globe Newswire (Thu, 15-Oct 7:00 AM ET)
Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations
Globe Newswire (Wed, 30-Sep 7:00 AM ET)
Globe Newswire (Tue, 8-Sep 7:00 AM ET)
Globe Newswire (Fri, 14-Aug 7:00 AM ET)
Globe Newswire (Mon, 3-Aug 7:00 AM ET)
Globe Newswire (Thu, 16-Jul 7:00 AM ET)
Market Chameleon (Thu, 16-Apr 3:29 AM ET)
Market Chameleon (Tue, 3-Feb 6:43 AM ET)
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
Adlai Nortye Group Ltd. - American Depositary Shares trades on the NASDAQ stock market under the symbol ANL.
As of October 15, 2026, ANL stock price climbed to $12.09 with 828,639 million shares trading.
ANL has a beta of 3.23, meaning it tends to be more sensitive to market movements. ANL has a correlation of 0.05 to the broad based SPY ETF.
ANL has a market cap of $778.57 million. This is considered a Small Cap stock.
In the last 3 years, ANL traded as high as $17.48 and as low as $.88.
The top ETF exchange traded funds that ANL belongs to (by Net Assets): CANC, BBC, EWX, GXC, APIE.
ANL has outperformed the market in the last year with a return of +619.6%, while the SPY ETF gained +17.7%. In the last 3 month period, ANL beat the market returning +31.4%, while SPY returned +2.9%. However, in the most recent 2 weeks ANL has underperformed the stock market by returning -24.4%, while SPY returned +1.2%.
ANL support price is $10.13 and resistance is $11.63 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANL shares will trade within this expected range on the day.